Wedbush raised the firm’s price target on Viridian Therapeutics to $40 from $39 and keeps an Outperform rating on the shares. The firm says that overall, the Q4 report was largely uneventful as anticipated. Most important in the update, Viridian reiterated its timelines for all key programs which includes pivotal VRDN-001 data in active TED by mid-2024, and chronic TED by year-end 2024.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on VRDN:
- Viridian Therapeutics names Jennifer Tousignant chief legal officer
- Insider Trading: Viridian (NASDAQ:VRDN) Sees Huge Insider Buy
- Viridian Therapeutics price target lowered to $39 from $40 at Wedbush
- Viridian Therapeutics 7.14M share Spot Secondary priced at $21.00
- Viridian announces offering of common stock, Series B preferred stock